Eli Lilly and Company (LLY): A Bull Case Theory
We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...
BioSpace13h
Explainer: The Thriving Shadow Market of GLP-1s for Weight Loss
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...
WDRB1d
The 2 sides of Ozempic — weight loss success stories and health nightmares in Kentucky
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
Modern Healthcare1d
Ozempic, Wegovy maker responds to Hims & Hers Super Bowl ad
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Rolling Out1d
Illegal weight loss drug sales flourish on social media
Discover why people risk buying Ozempic and similar weight loss medications through social media, the devastating consequences, and legitimate ways to treatment ...
Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
FierceBiotech1d
Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
The Physicians Really Are Healing Themselves, With Ozempic
There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...
stockhead1d
Ozempic’s PBS push could shake up ASX food stocks, and here’s how
Big pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions, and more ...
BioSpace4d
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Lilly's Growth in Diabetes and Obesity, and Strong Oncology and Immunology Drugs Create a Wide Moat
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...